Brokerage Views: Bajaj Finance, Vedanta, NTPC, IndiGo are in focus today
Jefferies, JP Morgan and Morgan Stanley have maintained buy or overweight ratings on Bajaj Finance. CLSA has upgraded the NBFC stock to reduce from sell.
Most brokerages are upbeat on Bajaj Finance and NTPC after the announcement of financial results by both Nifty50 companies during the weekend. However, they are divided on the pharma sector.
Here's JPMorgan, Morgan Stanley, CLSA, and Citi make of some of the key stocks today:
Bajaj Finance
Jefferies, JP Morgan and Morgan Stanley have maintained 'buy' or overweight ratings on Bajaj Finance. CLSA has upgraded the NBFC stock to 'reduce' from 'sell'.
Brokerages | Rating | Price Target |
CLSA | Reduce | INR 6000 |
JP Morgan | Overweight | INR 9000 |
Morgan Stanley | Overweight | INR 8000 |
Jefferies | Buy | INR 7280 |
HSBC | Reduce | INR 5460 |
NTPC
CLSA, Citi, and Jefferies have each maintained a 'buy' on NTPC.
According to CLSA, the company would be a leader in energy transition and is on track for its lofty goal of 60 GW by FY32.
Brokerages | Rating | Price Target |
CLSA | Buy | INR 195 |
Jefferies | Buy | INR 195 |
CITI | Buy | INR 202 |
According to CITI, NTPC’s management expects to end FY23 with under-recoveries of Rs 250 crore. Its renewable asset monetisation is in line with the management’s March 2023 guidance, according to the brokerage.
Vedanta
Brokerages like CLSA and CITI are skeptical on Vedanta, with 'reduce' and 'neutral' ratings respectively.
Brokerages | Rating | Price Target |
CLSA | Reduce | INR 290 |
CITI | Neutral | INR 335 |
Leverage concerns appear to be abating, according to Citi. The company’s dividend outflow for FY23 so far would amount to $3.7 billion, according to the brokerage.
Interglobe Aviation (IndiGo)
JPMorgan maintains an 'overweight' on Interglobe Aviation with a target price of Rs 2,350 apiece. The brokerage expects industry demand-supply to result in a favourable yield.
The overall demand remains robust even at a higher yield, according to JPMorgan.
HDFC AMC
Morgan Stanley has maintained an 'equal-weight' rating on HDFC AMC with a target price of Rs 2,100 apiece. Market regulator SEBI may ask asset managers to pass on some benefits of scale to investors, which could hurt revenue while absorbing certain expenses like GST and brokerage fees, according to the brokerage.
JP Morgan on pharma stocks
The brokerage reinstates an Overweight stance on Sun Pharmaceutical and Cipla each with a target price of Rs 1200 and Rs 1210 apiece, respectively. While it maintains and Underweight rating on Dr Reddy's Laboratories and Lupin each with a target of Rs 3800 and Rs 660 per share, respectively.
DLF
Brokerages | Rating | Price Target |
CLSA | Buy | INR 470 |
Jefferies | Buy | INR 435 |
Morgan Stanley | Overweight | INR 417 |
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.